QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
NASDAQ:CRBU

Caribou Biosciences - CRBU Stock Forecast, Price & News

$9.35
+0.21 (+2.30%)
(As of 12/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$9.00
$9.52
50-Day Range
$8.34
$11.01
52-Week Range
$4.89
$19.32
Volume
493,156 shs
Average Volume
679,642 shs
Market Capitalization
$570.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.80

Caribou Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
197.3% Upside
$27.80 Price Target
Short Interest
Healthy
6.45% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.15mentions of Caribou Biosciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$108,000 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.73) to ($1.93) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

575th out of 1,023 stocks

Biological Products, Except Diagnostic Industry

92nd out of 170 stocks

About Caribou Biosciences

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.

Receive CRBU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Caribou Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CRBU Stock News Headlines

Caribou Biosciences, Inc. (NASDAQ:CRBU) Short Interest Update
Caribou Biosciences (NASDAQ:CRBU) Price Target Cut to $37.00
Caribou Biosciences Inc
See More Headlines
Receive CRBU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Caribou Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CRBU Company Calendar

Last Earnings
11/08/2021
Today
12/06/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/20/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRBU
Fax
N/A
Employees
2,021
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$27.80
High Stock Price Forecast
$37.00
Low Stock Price Forecast
$19.00
Forecasted Upside/Downside
+197.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-66,920,000.00
Net Margins
-714.82%
Pretax Margin
-712.30%

Debt

Sales & Book Value

Annual Sales
$9.60 million
Book Value
$6.44 per share

Miscellaneous

Free Float
55,817,000
Market Cap
$570.37 million
Optionable
Not Optionable
Beta
1.66

Key Executives

  • Dr. Rachel E. Haurwitz Ph.D.Dr. Rachel E. Haurwitz Ph.D. (Age 36)
    Co-Founder, CEO, Pres & Director
    Comp: $858.05k
  • Mr. Jason V. O'Byrne M.B.A. (Age 53)
    Chief Financial Officer
    Comp: $586.36k
  • Ms. Barbara G. McClung Esq.Ms. Barbara G. McClung Esq. (Age 67)
    J.D., Chief Legal Officer & Corp. Sec.
    Comp: $608.38k
  • Mr. Daniel Poon
    VP of Operations & Information Technology
  • Dr. Justin Skoble
    VP of Technical Operations
  • Dr. Steven B. KannerDr. Steven B. Kanner (Age 63)
    Chief Scientific Officer
  • Ms. Amy Figueroa C.F.A.
    VP of Investor Relations & Corp. Communications
  • Ms. Cindy Hayashi
    VP of HR
  • Ms. Ruhi A. Khan M.B.A. (Age 47)
    Chief Bus. Officer
  • Dr. Syed Ali-aamir Rizvi M.D. (Age 55)
    Chief Medical Officer













CRBU Stock - Frequently Asked Questions

Should I buy or sell Caribou Biosciences stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Caribou Biosciences in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRBU shares.
View CRBU analyst ratings
or view top-rated stocks.

What is Caribou Biosciences' stock price forecast for 2023?

6 equities research analysts have issued twelve-month price objectives for Caribou Biosciences' shares. Their CRBU share price forecasts range from $19.00 to $37.00. On average, they expect the company's stock price to reach $27.80 in the next twelve months. This suggests a possible upside of 198.9% from the stock's current price.
View analysts price targets for CRBU
or view top-rated stocks among Wall Street analysts.

How have CRBU shares performed in 2022?

Caribou Biosciences' stock was trading at $15.09 at the start of the year. Since then, CRBU shares have decreased by 38.4% and is now trading at $9.30.
View the best growth stocks for 2022 here
.

Are investors shorting Caribou Biosciences?

Caribou Biosciences saw a decline in short interest in November. As of November 15th, there was short interest totaling 3,280,000 shares, a decline of 9.4% from the October 31st total of 3,620,000 shares. Based on an average daily trading volume, of 666,600 shares, the days-to-cover ratio is presently 4.9 days. Currently, 6.5% of the company's stock are sold short.
View Caribou Biosciences' Short Interest
.

When is Caribou Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 20th 2023.
View our CRBU earnings forecast
.

How were Caribou Biosciences' earnings last quarter?

Caribou Biosciences, Inc. (NASDAQ:CRBU) released its earnings results on Monday, November, 8th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.34. The firm earned $3.98 million during the quarter, compared to analysts' expectations of $3 million. Caribou Biosciences had a negative trailing twelve-month return on equity of 26.66% and a negative net margin of 714.82%.

When did Caribou Biosciences IPO?

(CRBU) raised $202 million in an initial public offering (IPO) on Friday, July 23rd 2021. The company issued 13,500,000 shares at a price of $14.00-$16.00 per share.

What is Caribou Biosciences' stock symbol?

Caribou Biosciences trades on the NASDAQ under the ticker symbol "CRBU."

Who are Caribou Biosciences' major shareholders?

Caribou Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (7.34%), Pictet Asset Management SA (5.39%), Vanguard Group Inc. (4.19%), State Street Corp (3.93%), Elmwood Wealth Management Inc. (3.88%) and Farallon Capital Management LLC (1.47%). Insiders that own company stock include Barbara G Mcclung, Ryan Fischesser and Steven Kanner.
View institutional ownership trends
.

How do I buy shares of Caribou Biosciences?

Shares of CRBU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Caribou Biosciences' stock price today?

One share of CRBU stock can currently be purchased for approximately $9.30.

How much money does Caribou Biosciences make?

Caribou Biosciences (NASDAQ:CRBU) has a market capitalization of $567.30 million and generates $9.60 million in revenue each year. The company earns $-66,920,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis.

How many employees does Caribou Biosciences have?

The company employs 2,021 workers across the globe.

How can I contact Caribou Biosciences?

The official website for the company is cariboubio.com. The company can be reached via phone at 510-982-6030 or via email at investor.relations@cariboubio.com.

This page (NASDAQ:CRBU) was last updated on 12/6/2022 by MarketBeat.com Staff